SEC Filing Summary: Form 8-K
Business Context and Reporting Period
Company: AspenBio Pharma, Inc. (Note: Request metadata referenced "Riot Platforms, Inc.", but the filing text identifies the registrant as AspenBio Pharma, Inc.)
Date of Report: December 23, 2011
Reporting Period: Current report filed December 28, 2011, regarding events on December 23, 2011.
Event: Entry into a Material Definitive Agreement for a registered direct offering.
Key Financial Metrics
This filing details a capital raise rather than operational performance metrics. Key figures include:
- Gross Proceeds: Approximately $1,637,100.
- Net Proceeds: Approximately $1.5 million (after fees and expenses).
- Offering Size: Up to $2,000,000 aggregate securities.
- Price per Security: $1.02.
- Placement Agent Fees: $111,215.
- Expense Reimbursement: $16,371.
- Warrant Exercise Price: $1.22 per share.
Note: The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change is the execution of a Placement Agency Agreement with Ladenburg Thalmann & Co. Inc. for a registered direct offering. Each security sold consists of one share of common stock and one warrant to purchase one share of common stock. The closing of the sale is expected on or about December 30, 2011.
Outlook, Risks, and Unusual Items
Management Commentary: The offering is being conducted pursuant to a shelf registration statement (Form S-3). A press release announcing the offering was issued on December 27, 2011.
Warrant Terms: Warrants are exercisable six months after closing and expire sixty months thereafter.
Risks/Contingencies: The closing is subject to the satisfaction of customary closing conditions. The filing states that the description of terms is brief and qualified by reference to the attached exhibits.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received (expected ~$1.5 million).
- Confirm the number of shares and warrants issued based on the $1.02 price point.
- Review the full Placement Agency Agreement (Exhibit 1.1) and Securities Purchase Agreement (Exhibit 10.1) for specific covenants.
- Check subsequent filings for the impact of this capital raise on the company's cash position and dilution.